Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Betfred Deepens Technology Partnership With Sportradar to Ensure a Long-Term and Sustainable Retail Betting Offering 4-02-2026, 16:00

Bitdeer Completes Testing of its Latest SEAL02 Bitcoin Mining Chip 26-09-2024, 19:00